DNA Nanobots, a biotechnology company pioneering self-assembling nanoscale therapeutics, has secured $3.5 million in funding from a prominent family office, strengthening its financial runway for the next 18 months. The investment marks a key step forward in advancing the company’s non-viral gene delivery platform toward clinical readiness.
The funding represents a significant portion of DNA Nanobots’ ongoing $5 million Seed round, enabling the company to progress core research programs and achieve major technical milestones through 2026. The company is currently seeking an additional $1.5 million to complete the round and move into IND-enabling studies ahead of first-in-human trials.
“We are very pleased to have successfully completed $3.5 million of our $5 million Seed round,” said Jim Lynch, Chief Executive Officer of DNA Nanobots. “This financing provides the capital needed to advance our programs and execute key value-creating milestones. We appreciate the continued support from investors who share our confidence in the strategy and the team.”
Advancing a new class of gene delivery
At the core of DNA Nanobots’ technology is precise DNA self-assembly, often referred to as DNA origami. This approach enables the creation of programmable nanobots designed to transport and release genetic payloads directly into diseased cells, offering the potential to deliver genes previously considered undeliverable while reducing systemic toxicity.
The newly secured capital will be directed toward advancing pre-clinical studies, expanding in-house production capabilities, strengthening the company’s intellectual property portfolio, and hiring specialized talent across molecular biology, nanotechnology, and engineering.
The investment also reflects growing momentum within Ohio’s life sciences ecosystem. “It’s encouraging to see capital flowing into Ohio-based companies, including innovative Ohio State spinouts,” said Eddie Pauline, President and CEO of the Ohio Life Sciences Association, highlighting DNA Nanobots as a signal of the region’s research and commercialization strength.
Preparing for clinical translation
With anchor funding in place, DNA Nanobots is focused on building the operational and scientific foundation required for clinical translation. Completing the Seed round will allow the company to initiate regulatory preparation and scale manufacturing processes critical for human trials.
By prioritizing reproducibility, manufacturability, and precision targeting, DNA Nanobots aims to address long-standing challenges associated with viral vectors, including safety concerns and payload limitations.
Editorial View: Why DNA Nanobots’ Progress Is Noteworthy
Gene therapy continues to evolve rapidly, but delivery remains one of its most persistent bottlenecks. In this context, DNA Nanobots’ focus on non-viral, programmable delivery systems represents a meaningful departure from conventional approaches. Precision targeting at the nanoscale has the potential to expand the range of treatable diseases while improving safety profiles.
The company’s emphasis on building manufacturing and intellectual property alongside pre-clinical validation reflects a disciplined path toward long-term value creation. Rather than racing prematurely into the clinic, DNA Nanobots is laying the groundwork required for scalable and repeatable therapeutics.
If successful, this platform could influence how future gene therapies are designed and delivered—particularly for indications where viral vectors fall short. Backed by patient capital and operating within a strengthening regional biotech ecosystem, DNA Nanobots appears well-positioned for its next phase of growth.
If you need further assistance or have any corrections, please reach out to editor@thetimesmag.com.
